Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Abstract

Acute graft-versus-host disease (aGVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the mechanisms of aGVHD are not well understood. We aim to investigate the roles of the three angiogenic factors: angiopoietin-1 (Ang-1), Ang-2 and vascular endothelial growth factor (VEGF) in the development of aGVHD. Twenty-one patients who underwent allo-HSCT were included in our study. The dynamic changes of Ang-1, Ang-2 and VEGF were monitored in patients before and after allo-HSCT. In vitro, endothelial cells (ECs) were treated with TNF-β in the presence or absence of Ang-1, and then the Ang-2 level in the cell culture medium and the tubule formation by ECs were evaluated. After allo-HSCT, Ang-1, Ang-2 and VEGF all exhibited significant variation, suggesting these factors might be involved in the endothelial damage in transplantation. Patients with aGVHD had lower Ang-1 level at day 7 but higher Ang-2 level at day 21 than those without aGVHD, implying that Ang-1 may play a protective role in early phase yet Ang-2 is a promotion factor to aGVHD. In vitro, TNF-β promoted the release of Ang-2 by ECs and impaired tubule formation of ECs, which were both weakened by Ang-1, suggesting that Ang-1 may play a protective role in aGVHD by influencing the secretion of Ang-2, consistent with our in vivo tests. It is concluded that monitoring changes of these factors following allo-HSCT might help to identify patients at a high risk for aGVHD.

Keywords

allogeneic hematopoietic stem cell transplantation / acute graft-versus-host disease / angiogenic factors / endothelial damage

References

[1] TichelliA, GratwohlA. Vascular endothelium as "novel" target of graft-versus-host disease. Best Pract Res Clin Haematol, 2008, 21(2): 139-148 PMID: 18503982

[2] DumlerJS, BeschornerWE, FarmerER, et al. . Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol, 1989, 135(6): 1097-1103 PMCID: 1880480 PMID: 2596572

[3] SalatC, HollerE, KolbHJ, et al. . Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant, 1997, 19(9): 909-914 PMID: 9156265

[4] BiedermannBC, SahnerS, GregorM, et al. . Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet, 2002, 359(9323): 2078-2083 PMID: 12086762

[5] PenackO, HenkeE, SuhD, et al. . Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst, 2010, 102(12): 894-908 PMCID: 2886094 PMID: 20463307

[6] PenackO, SocieG, van den BrinkMR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood, 2011, 117(16): 4181-4189 PMID: 21258010

[7] MedingerM, TichelliA, BucherC, et al. . GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM. Bone Marrow Transplant, 2013, 48(5): 715-721 PMID: 23085826

[8] ThomasM, AugustinHG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis, 2009, 12(2): 125-137 PMID: 19449109

[9] FagianiE, ChristoforiG. Angiopoietins in angiogenesis. Cancer Lett, 2013, 328(1): 18-26 PMID: 22922303

[10] FiedlerU, ScharpfeneckerM, KoidlS, et al. . The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood, 2004, 103(11): 4150-4156 PMID: 14976056

[11] LinaresPM, ChaparroM, GisbertJP. Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. J Crohns Colitis, 2014, 8(3): 183-190 PMID: 23859759

[12] SinnathambyT, YunJ, Clavet-LanthierME, et al. . VEGF and angiopoietins promote inflammatory cell recruitment and mature blood vessel formation in murine sponge/Matrigel model. J Cell Biochem, 2015, 116(1): 45-57 PMID: 25145474

[13] ThomasKA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem, 1996, 271(2): 603-606 PMID: 8557658

[14] ReindersME, ShoM, IzawaA, et al. . Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest, 2003, 112(11): 1655-1665 PMCID: 281640 PMID: 14660742

[15] UedaN, ChiharaD, KohnoA, et al. . Predictive value of circulating angiopoietin-2 for endothelial damage related complications in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2014, 20(9): 1335-1340 PMID: 24796281

[16] LuftT, DietrichS, FalkC, et al. . Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood, 2011, 118(6): 1685-1692 PMID: 21636856

[17] NomuraS, IshiiK, InamiN, et al. . Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant, 2008, 14(7): 766-774 PMID: 18541195

[18] MinCK, KimSY, LeeMJ, et al. . Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant, 2006, 38(2): 149-156 PMID: 16751784

[19] NachbaurD, SchumacherP, AubergerJ, et al. . Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2007, 13(8): 942-947 PMID: 17640598

[20] KimD L N, LeeMH, et al. . Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant, 2008, 14(12): 1408-1416 PMID: 19041064

[21] HollerE, KolbHJ, MollerA, et al. . Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood, 1990, 75(4): 1011-1016 PMID: 2405918

[22] FerraraJL, DeegHJ. Graft-versus-host disease. N Engl J Med, 1911, 324(10): 667-674

[23] PrzepiorkaD, WeisdorfD, MartinP, et al. . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant, 1995, 15(6): 825-828 PMID: 7581076

[24] FerraraJL, LevineJE, ReddyP, et al. . Graft-versus-host disease. Lancet, 2009, 373(9674): 1550-1561 PMCID: 2735047 PMID: 19282026

[25] WitzenbichlerB, WestermannD, KnueppelS, et al. . Protective role of angiopoietin-1 in endotoxic shock. Circulation, 2005, 111(1): 97-105 PMID: 15611372

[26] BhandariV, Choo-WingR, LeeCG, et al. . Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med, 2006, 12(11): 1286-1293 PMCID: 2768268 PMID: 17086189

[27] FiedlerU, ReissY, ScharpfeneckerM, et al. . Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med, 2006, 12(2): 235-239 PMID: 16462802

[28] McCarterSD, LaiPF, SuenRS, et al. . Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp Biol Med (Maywood), 2006, 231(6): 985-991

[29] Van der HeijdenM, van Nieuw AmerongenGP, KoolwijkP, et al. . Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax, 2008, 63(10): 903-909 PMID: 18559364

[30] NovotnyNM, LahmT, MarkelTA, et al. . Angiopoietin-1 in the treatment of ischemia and sepsis. Shock, 2009, 31(4): 335-341 PMID: 18791498

[31] Van der HeijdenM, van Nieuw AmerongenGP, ChedamniS, et al. . The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. Expert Opin Ther Targets, 2009, 13(1): 39-53 PMID: 19063705

[32] FiedlerU, AugustinHG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol, 2006, 27(12): 552-558 PMID: 17045842

[33] PaulusP, JenneweinC, ZacharowskiK. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis. Biomarkers, 2011, 16(1): 11-21

[34] PageAV, LilesWC. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence, 2013, 4(6): 507-516 PMID: 23669075

[35] BrindleNP, SaharinenP, AlitaloK. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res, 2006, 98(8): 1014-1023 PMCID: 2270395 PMID: 16645151

[36] AlfieriA, WatsonJJ, KammererRA, et al. . Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis. Crit Care, 2012, 16(5): R182 PMCID: 3682284 PMID: 23036162

[37] DietrichS, FalkCS, BennerA, et al. . Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant, 2013, 19(1): 22-27 PMID: 23041600

[38] PorkholmM, BonoP, Saarinen-PihkalaUM, et al. . Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant, 2013, 48(1): 50-55 PMID: 22659681

[39] MoiseevIS, LapinSV, SurkovaEA, et al. . Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2013, 19(12): 1677-1682 PMID: 24035780

[40] LunnRA, SumarN, BansalAS, et al. . Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology, 2005, 10(2): 107-114 PMID: 16019456

[41] AzarpiraN, DehghaniM, DaraiM. The interleukin-6 and vascular endothelial growth factor in hematopoietic stem cell transplantation. Saudi J Kidney Dis Transpl, 2012, 23(3): 521-525 PMID: 22569438

[42] LobovIB, BrooksPC, LangRA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A, 2002, 99(17): 11205-11210 PMCID: 123234 PMID: 12163646

[43] OshimaY, OshimaS, NambuH, et al. . Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J, 2005, 19(8): 963-965 PMID: 15802489